Kefah Mokbel, Chair of Breast Cancer Surgery at London Breast Institute and Honorary Professor of Medicine at Cardiff University School of Medicine, shared a post on LinkedIn:
“Important new evidence supporting hypofractionation in early breast cancer.
A recent randomised phase III study published in The Lancet shows that 3-week hypofractionated locoregional radiotherapy (40 Gy in 15 fractions) is non-inferior to the conventional 5-week schedule (50 Gy in 25 fractions) with respect to the risk of arm lymphoedema. (The Lancet)
These findings provide reassuring data that shortening treatment duration does not increase lymphoedema risk, while offering clear benefits for patients and healthcare systems, including greater convenience and improved radiotherapy capacity.
This adds to the growing body of evidence supporting moderate hypofractionation as a standard approach in early breast cancer, including when locoregional irradiation is indicated.”
Title: 5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial
Authors: Sofia Rivera, Robabeh Ghodssighassemabadi, Guillaume Auzac, Thomas Brion, Youlia Kirova, Séverine Racadot, Mohamed Benchalal, Jean-Baptiste Clavier, Claire Charra Brunaud, Anais Groulier, Delphine Argo-Leignel, Karine Peignaux, Ahmed Benyoucef, David Pasquier, Philippe Guilbert, Aurore Goineau, Agnes Tallet, Marie Bergeaud, Assia Lamrani-Ghaouti, Stefan Michiels.
Other articles featuring Kefah Mokbel on OncoDaily.